Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Inclusion Criteria: * Female * Diagnosis of adenocarcinoma of the lung * Patient has had at least one core biopsy of her tumor * Must be willing to undergo epidermal growth factor receptor (EGFR) mutation testing of her tumor * Stage four (IV) or three (III) B non-small cell lung cancer * Non-smoker or former smoker. Non-smoker is defined as a person who smoked 100 or less cigarettes in her lifetime while a former smoker is defined as a person who has quit smoking one or more years ago. * Three or more weeks since last radiation therapy * Three or more weeks since last major surgery * Must at least be able to walk and capable of taking care of herself although unable to carry out work activities * Life expectancy of 8 weeks or more * Blood tests that show kidneys, liver and bone marrow to be working adequately * Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the entire time enrolled in study Exclusion Criteria: * Prior exposure to Tarceva (OSI-774, erlotinib) * Uncontrolled central nervous system problems * Prior chemotherapy regimen * Difficulty swallowing * A disease or disorder that interferes with ability to digest and absorb food * Incomplete healing of previous oncologic or other major surgery * Significant medical history or unstable medical condition such as heart failure, active infection, uncontrolled high blood pressure * Pregnant or breast feeding * A medical condition that could make it unsafe for patient to participate in this study